IMNN's logo.
Ticker Symbol: IMNN

Imunon Inc

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0000749647

Company Profile

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 997 Lenox Dr Ste 100
CEO: Michael Tardugno
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.03
Change: -$0.01 ( -0.96%)
Days Range: $1.01 - $1.06
Beta: 0.92
52wk. High: $1.72
52wk. Low: $0.91
Ytd. Change -23.92%
50 Day Moving Average: $1.06
200 Day Moving Average: $1.21
Shares Outstanding: 9367855

Valuation

Market Cap: 964.9M
PE Ratio: -0.28
EPS (TTM): -3.67

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A